Document is current

Article History

Received: 12 December 2020

Revised: 27 January 2021

Accepted: 16 March 2021

First Online: 2 May 2021

Declarations

:

: The scientific guarantor of this publication is Masoom A. Haider.

: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

: The authors Xin Dong, who holds a master’s of science degree in mathematics, and Dr. Dominik Deniffel have significant statistical expertise.

: Written informed consent was obtained from all subjects (patients) in this study.

: This retrospective, multicenter study was approved by our institutional review board and informed consent was obtained. Our study population was retrospectively selected from a prospective multi-institutional trial (COMPASS, NCT02750657) between December 2015 and April 2018.

: This cohort has been previously included in studies focusing on radiomics features in pre-chemotherapy CT scans and genomic profiling.ReferencesSalinas-Miranda E, Khalvati F, Namdar K, et al (2020) Validation of prognostic radiomic features from resectable pancreatic ductal adenocarcinoma in patients with advanced disease undergoing chemotherapy. <i>Can Assoc Radiol J</i>.O’Kane GM, Grünwald BT, Jang G-H, et al (2020) GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer<i>. Clin Cancer Res</i> 26:4901–4910.Aung KL, Fischer SE, Denroche RE, et al (2018) Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. <i>Clin Cancer Res</i> 24:1344–1354.

: • Retrospective• diagnostic or prognostic study• multicenter study